Journal of Gastroenterology

, Volume 53, Issue 10, pp 1142–1150 | Cite as

Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group

  • Keiji Tsuji
  • Masayuki Kurosaki
  • Jun Itakura
  • Nami Mori
  • Shintaro Takaki
  • Chitomi Hasebe
  • Takehiro Akahane
  • Kouji Joko
  • Hitoshi Yagisawa
  • Jirou Takezawa
  • Ryou Nakata
  • Atsunori Kusakabe
  • Yuji Kojima
  • Hiroyuki Kimura
  • Takashi Tamada
  • Haruhiko Kobashi
  • Akeri Mitsuda
  • Masahiko Kondou
  • Chikara Ogawa
  • Yasushi Uchida
  • Tetsuro Sohda
  • Ryouichi Narita
  • Namiki Izumi
Original Article—Liver, Pancreas, and Biliary Tract



We aimed to describe the real-world efficacy and safety of combination therapy with ledipasvir and sofosbuvir (LDV/SOF) for chronic hepatitis C virus (HCV) genotype 1 (GT1) infection.


This retrospective analysis of a prospective, nationwide, multicenter registry included GT1-infected patients treated with LDV/SOF for 12 weeks. We assessed the rate of sustained virological response at 12 weeks post-treatment (SVR12), incidence of adverse events, and serum markers of hepatocellular carcinoma (HCC).


Among the 1461 patients included (mean age, 69 years; 29.5% aged > 75 years; cirrhosis, 23.8%; history of treatment for HCC, 10.9%), the overall SVR12 rate was 98.4% (1438/1461). Factors associated with treatment failure were cirrhosis (odds ratio, 4.19; p = 0.014) and resistance-associated substitutions (RASs) in NS5A at baseline (odds ratio, 7.78; p = 0.0004). The SVR12 rate in patients with cirrhosis and NS5A RASs was 93.0% compared to 100% in patients without cirrhosis or NS5A RASs. In patients with SVR, the levels of alpha-fetoprotein (AFP), AFP-L3, and Mac-2 binding protein glycosylation isomer (M2BPGi) decreased from baseline to end of treatment (from 13.4 ± 37.6 to 6.0 ± 10.6 ng/mL, p < 0.0001; from 2.2 ± 4.9 to 1.5 ± 6.3%, p < 0.005; and from 3.6 ± 3.7 to 2.0 ± 3.5 cut-off index, p < 0.0001; respectively). Adverse events were rare and not associated with age. No decrease in estimated glomerular filtration rate was observed in patients with baseline chronic kidney disease stage 3.


LDV/SOF therapy is highly effective and safe in elderly Japanese patients with HCV GT1, even in the presence of cirrhosis or NS5A RASs. Patients with SVR may have a lower risk of HCC.


Chronic hepatitis C Ledipasvir Sofosbuvir Alpha-fetoprotein 



This study was supported by a Grant-in aid from the Japan Agency for Medical Research and Development (Grant number: 15fk0210007h0002).


  1. 1.
    Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671–5.CrossRefGoogle Scholar
  2. 2.
    Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687–95.CrossRefGoogle Scholar
  3. 3.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–94.CrossRefGoogle Scholar
  4. 4.
    American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C. Accessed 16 Sept 2016.
  5. 5.
    The Japan Society for Hepatology. JSH guidelines for management of hepatitis C virus infection (ver. 5.2). 2016. Accessed 15 Dec 2016.
  6. 6.
    Asahina Y, Tsuchiya K, Nishimura T, et al. α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–62.CrossRefGoogle Scholar
  7. 7.
    Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA. 2002;99:15584–9.CrossRefGoogle Scholar
  8. 8.
    Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:724–8.CrossRefGoogle Scholar
  9. 9.
    Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.CrossRefGoogle Scholar
  10. 10.
    Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62.CrossRefGoogle Scholar
  11. 11.
    Izumi N. Efficacy of daclatasvir in hepatitis C virus. Exp Rev Anti-Infect Ther. 2014;12:1025–31.CrossRefGoogle Scholar
  12. 12.
    Itakura J, Kurosaki M, Hasebe C, et al. Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir/asunaprevir treatment failure. PLoS One. 2016;11:e0165339.CrossRefGoogle Scholar
  13. 13.
    Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomized, phase 3 trial. Lancet Infect Dis. 2015;15:645–53.CrossRefGoogle Scholar
  14. 14.
    Ogawa E, Furusyo N, Nomura H, et al. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 2017;52:845–54.CrossRefGoogle Scholar
  15. 15.
    Kanda T, Yasui S, Nakamura M, et al. Real- world experiences with the combination treatment of ledipasvir plus sofosbuvir for 12 weeks in HCV genotype 1-infected Japanese patients: achievement of a sustained virological response in previous users of peginterferon plus ribavirin with HCV NS3/4A inhibitors. Int J Mol Sci. 2017;18:906.CrossRefGoogle Scholar
  16. 16.
    Mizokami M, Dvory-Sobol H, Izumi N, et al. Resistance analyses of Japanese hepatitis C-infected patients receiving sofosbuvir or ledipasvir/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat. 2016;23:780–8.CrossRefGoogle Scholar
  17. 17.
    Oze T, Hiramatsu N, Yakushijin T, et al. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186–95.CrossRefGoogle Scholar
  18. 18.
    Tada T, Kumada T, Toyoda H, et al. Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. Hepatol Res. 2017;47:1021–31.CrossRefGoogle Scholar
  19. 19.
    Miyaki E, Hiraga N, Imamura M, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2016;46:758–64.CrossRefGoogle Scholar
  20. 20.
    Nguyen K, Jimenez M, Moghadam N, et al. Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct-acting antivirals. J Clin Transl Hepatol. 2017;5:43–9.PubMedGoogle Scholar
  21. 21.
    Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67:933–9.CrossRefGoogle Scholar
  22. 22.
    Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563–70.CrossRefGoogle Scholar
  23. 23.
    Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92–100.CrossRefGoogle Scholar
  24. 24.
    Toyoda H, Kumada T, Kaneoka Y, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49:223–32.CrossRefGoogle Scholar
  25. 25.
    Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54:650–9.CrossRefGoogle Scholar
  26. 26.
    Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–6.CrossRefGoogle Scholar
  27. 27.
    Yoshimi S, Ochi H, Murakami E, et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by invader assay. PLoS One. 2015;10:e0130022.CrossRefGoogle Scholar
  28. 28.
    Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.CrossRefGoogle Scholar
  29. 29.
    Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:360–7.CrossRefGoogle Scholar
  30. 30.
    Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702–26.CrossRefGoogle Scholar
  31. 31.
    Akuta N, Sezaki H, Suzuki F, et al. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 2017;89:284–90.CrossRefGoogle Scholar
  32. 32.
    Sasaki R, Yamasaki K, Abiru S, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One. 2015;10:e129053.Google Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  • Keiji Tsuji
    • 1
  • Masayuki Kurosaki
    • 2
  • Jun Itakura
    • 2
  • Nami Mori
    • 1
  • Shintaro Takaki
    • 1
  • Chitomi Hasebe
    • 3
  • Takehiro Akahane
    • 4
  • Kouji Joko
    • 5
  • Hitoshi Yagisawa
    • 6
  • Jirou Takezawa
    • 7
  • Ryou Nakata
    • 8
  • Atsunori Kusakabe
    • 9
  • Yuji Kojima
    • 10
  • Hiroyuki Kimura
    • 11
  • Takashi Tamada
    • 12
  • Haruhiko Kobashi
    • 13
  • Akeri Mitsuda
    • 14
  • Masahiko Kondou
    • 15
  • Chikara Ogawa
    • 16
  • Yasushi Uchida
    • 17
  • Tetsuro Sohda
    • 18
  • Ryouichi Narita
    • 19
  • Namiki Izumi
    • 2
  1. 1.Department of GastroenterologyHiroshima Red Cross Hospital and Atomic-bomb Survivors HospitalHiroshimaJapan
  2. 2.Department of Gastroenterology and HepatologyMusashino Red Cross HospitalTokyoJapan
  3. 3.Department of GastroenterologyJapanese Red Cross Asahikawa HospitalAsahikawaJapan
  4. 4.Department of GastroenterologyJapanese Red Cross Ishinomaki HospitalIshinomakiJapan
  5. 5.Center for Liver-Biliary-Pancreatic DiseaseMatsuyama Red Cross HospitalMatsuyamaJapan
  6. 6.Department of GastroenterologyJapanese Red Cross Akita HospitalAkitaJapan
  7. 7.Department of Internal MedicineJapanese Red Cross Haramachi HospitalHaramachiJapan
  8. 8.Department of GastroenterologyJapanese Red Cross Medical CenterTokyoJapan
  9. 9.Department of GastroenterologyJapanese Red Cross Nagoya Daini HospitalNagoyaJapan
  10. 10.Department of HepatologyJapanese Red Cross Ise HospitalIseJapan
  11. 11.Department of GastroenterologyJapanese Red Cross Kyoto Daiichi HospitalKyotoJapan
  12. 12.Department of GastroenterologyTakatsuki Red Cross HospitalTakatsukiJapan
  13. 13.Department of GastroenterologyJapanese Red Cross Okayama HospitalOkayamaJapan
  14. 14.Department of GastroenterologyJapanese Red Cross Tottori HospitalTottoriJapan
  15. 15.Department of GastroenterologyJapanese Red Cross Otsu HospitalOtsuJapan
  16. 16.Department of GastroenterologyTakamatsu Red Cross HospitalTakamatsuJapan
  17. 17.Department of GastroenterologyMatsue Red Cross HospitalMatsueJapan
  18. 18.Department of HepatologyJapanese Red Cross Fukuoka HospitalFukuokaJapan
  19. 19.Department of GastroenterologyOita Red Cross HospitalOitaJapan

Personalised recommendations